Drug Research
Drug Discovery & Development

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
106-120 of 4547 results
FDA accepts for filing Icon’s NDA for Dexycu drug therapy
The US Food and Drug Administration (FDA) has accepted for filing Icon Bioscience (IBI), recently submitted new drug application (NDA) for Dexycu (IBI-10090), a novel drug for treating inflammation associated with cataract surgery.
Drug Research > Drug Discovery & Development > News
Pfizer gets CRL on Epogen biosimilar from FDA
By PBR Staff Writer
The United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Pfizer in connection with its biosimilar candidate to Amgen’s anemia drug Epogen (epoetin alfa).
Drug Research > Drug Discovery & Development > News
Cancer frim Repare Therapeutics announces $68m Series A financing
Repare Therapeutics has secured $68m in a Series A financing round which it will use to advance its platform and pipeline of novel medicines that target genetically defined weaknesses of cancers.
Drug Research > Drug Discovery & Development > News
Rubius Therapeutics raises $120m to advance red blood cell technology
Rubius Therapeutics, which is developing red-cell therapeutics (RCTs) as a new class of medicines to address a range of indications, has raised $120m in a highly oversubscribed private financing.
Drug Research > Drug Discovery & Development > News
EIB supports development of BiondVax’s universal flu vaccine candidate
BiondVax Pharmaceuticals, which is developing a universal vaccine for all strains of influenza, has signed an agreement with the European Investment Bank (EIB) for a €20m loan.
Drug Research > Drug Discovery & Development > News
Axovant’s dementia drug granted FDA fast track designation
Axovant Sciences’ investigational drug nelotanserin has secured fast track designation from the US Food and Drug Administration (FDA) for the treatment of visual hallucinations disorder in dementia with Lewy bodies (DLB).
Drug Research > Drug Discovery & Development > News
Accenture, 1QBit work with Biogen to apply quantum computing to speed up drug discovery
Accenture and 1QBit have partnered with Biogen to develop a quantum-enabled molecular comparison application that could considerably improve advanced molecular design to accelerate drug discovery for complex neurological conditions like multiple sclerosis, Alzheimer’s, Lou Gehrig’s Disease and Parkinson’s.
Drug Research > Drug Discovery & Development > News
Domainex, Imperial College London expand cardiac therapy collaboration
Domainex has extended its partnership with Imperial College London to discover novel therapies that reduce heart muscle damage during heart attacks.
Drug Research > Drug Discovery & Development > News
Omeros’ OMS721 kidney drug gets FDA breakthrough therapy status
By PBR Staff Writer
Omeros’ MASP-2 inhibitor OMS721 has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of Immunoglobulin A (IgA) nephropathy.
Drug Research > Drug Discovery & Development > News
Selexis, TeneoBio sign deal to advance development of UniAbs targeting cancer
Selexis and TeneoBio have signed a service agreement to jointly advance the development of a new class of biologics, Human Heavy-Chain Antibodies (UniAbs) targeting cancer.
Drug Research > Drug Discovery & Development > News
Numerate, Takeda partner to generate clinical candidates using AI-driven drug discovery
Numerate has entered into a multi-year agreement with Takeda Pharmaceutical under which it will identify and deliver multiple clinical candidates by applying artificial intelligence (AI) at cloud scale.
Drug Research > Drug Discovery & Development > News
EC approves Johnson & Johnson's $30bn acquisition of Actelion
By PBR Staff Writer
The European Commission (EC) has approved Johnson & Johnson's proposed $30bn acquisition of Actelion Pharmaceuticals, subject to conditions
Drug Research > Drug Discovery & Development > News
Midatech signs deal with Novartis to investigate panobinostat to treat brain cancers
Midatech Pharma has inked a global licensing agreement with Novartis for the oncology compound panobinostat.
Drug Research > Drug Discovery & Development > News
GL Capital-led consortium to buy SciClone Pharmaceuticals
A consortium featuring entities affiliated with GL Capital Management GP, Bank of China Group Investment (BOCGI), CDH Investments, Ascendent Capital Partners and Boying will acquire all the outstanding shares of SciClone Pharmaceuticals for $11.18 per share in cash.
Drug Research > Drug Discovery & Development > News
Eleven Biotherapeutics to collaborate with Astrazeneca, National Cancer Institute
Eleven Biotherapeutics signed a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to assess its late-clinical-stage fusion protein Vicinium (VB4-845) combined with AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab) to treat nonmuscle invasive bladder cancer (NMIBC).
Drug Research > Drug Discovery & Development > News
106-120 of 4547 results